ArchivesMagazine - 03 Jun 2021Why GlaxoSmithKline could bid for Astra’s vaccine Glaxo’s response to Covid has been one of the broadest in the industry with two potential treatments as well as multiple vaccine candidates 03 June 2021|Feature|by Martin Gamble Share on Facebook Share on Bluesky Share on X (Twitter) Share by Email < Aveva eyes renewables as part of its digitisation growth strategy Major share overhang finally removed from Brunner > Issue: 03 Jun 2021 - Page 17 | Contents Next: Major share overhang finally removed from Brunner Previous: Aveva eyes renewables as part of its digitisation growth strategy Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. Share on Facebook Share on Bluesky Share on X (Twitter) Share by Email Martin Gamble Issue Contents Ask Tom Can I recycle tax-free pension withdrawals into a SIPP? Editor's View The clues in everyday life that give you an investing edge Education How to buy foreign shares and the key details you need Feature Why GlaxoSmithKline could bid for Astra’s vaccine The price is right: 5 stocks which could win big Funds Some of the best funds come in small packages Managers vs machines - are active funds worth the extra cost? Great Ideas SSE is a great way to play the green revolution Buy increasingly profitable safety and compliance firm Marlowe Flood of takeover bids boosts Odyssean Major share overhang finally removed from Brunner Hill & Smith posts faster growth and confirms full year view Investment Trusts Flexible investment trusts can protect you against inflation News Gold tops $1,900 again as it regains its haven credentials Aveva eyes renewables as part of its digitisation growth strategy Competitive pressures face new listing Made.com Spiralling housing demand causes price spikes in building materials
